KemPharm, Inc. (NASDAQ:KMPH) has been given a $13.00 price objective by equities researchers at Oppenheimer Holdings, Inc. in a research report issued to clients and investors on Thursday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Oppenheimer Holdings, Inc.’s price target indicates a potential upside of 306.25% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Roth Capital began coverage on shares of KemPharm in a research report on Wednesday, June 28th. They set a “buy” rating and a $8.00 price target on the stock. Zacks Investment Research cut shares of KemPharm from a “hold” rating to a “sell” rating in a research report on Tuesday, May 16th. Royal Bank Of Canada set a $8.00 price target on shares of KemPharm and gave the company a “buy” rating in a research report on Wednesday, April 12th. ValuEngine upgraded shares of KemPharm from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 1st. Finally, Canaccord Genuity set a $7.00 price target on shares of KemPharm and gave the company a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $8.10.

Shares of KemPharm (KMPH) traded up 6.67% during midday trading on Thursday, reaching $3.20. The company had a trading volume of 54,016 shares. The company has a 50 day moving average price of $3.48 and a 200-day moving average price of $3.92. KemPharm has a one year low of $2.90 and a one year high of $5.50. The firm’s market capitalization is $46.90 million.

KemPharm (NASDAQ:KMPH) last issued its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.19. On average, analysts anticipate that KemPharm will post ($2.80) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/08/13/kempharm-inc-kmph-given-a-13-00-price-target-at-oppenheimer-holdings-inc.html.

In related news, CEO Travis C. Mickle purchased 8,000 shares of KemPharm stock in a transaction that occurred on Tuesday, June 20th. The shares were bought at an average price of $3.45 per share, for a total transaction of $27,600.00. Following the completion of the transaction, the chief executive officer now directly owns 1,629,612 shares of the company’s stock, valued at $5,622,161.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have purchased 10,775 shares of company stock worth $38,783 in the last quarter. 22.80% of the stock is owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its position in shares of KemPharm by 17.6% in the first quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock valued at $112,000 after buying an additional 3,414 shares in the last quarter. C WorldWide Group Holding A S boosted its position in shares of KemPharm by 10.1% in the first quarter. C WorldWide Group Holding A S now owns 181,699 shares of the specialty pharmaceutical company’s stock valued at $890,000 after buying an additional 16,699 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new position in shares of KemPharm during the first quarter valued at about $647,000. Institutional investors own 42.27% of the company’s stock.

KemPharm Company Profile

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.